Abstract
We experienced a 78-year-old woman who was diagnosed with hereditary transthyretin cardiac amyloidosis and administered patisiran for advanced heart failure refractory to tafamidis. The levels of N-terminal pro B-type natriuretic peptide and left ventricular mass index decreased following the six-month patisiran treatment without any complications. Patisiran might be a promising disease-modifying drug for hereditary transthyretin cardiac amyloidosis even in its advanced stage, although further evaluation in a large cohort is warranted.
Original language | English |
---|---|
Pages (from-to) | 177-180 |
Number of pages | 4 |
Journal | Journal of Cardiology Cases |
Volume | 23 |
Issue number | 4 |
DOIs | |
State | Published - 2021/04 |
Keywords
- Heart failure with preserved ejection fraction
- Transthyretin cardiac amyloidosis
- siRNA
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine